Trials / Completed
CompletedNCT04038710
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
An Observational Study of the Effects on Clinical Outcomes of Expanded Access Program of Vertex Triple Combination Therapy.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 8 (actual)
- Sponsor
- National Jewish Health · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational study of people with severe cystic fibrosis that are eligible for Vertex's triple combination therapy through its expanded access. Pulmonary health, intestinal health, and the overall health of individuals will be tracked for a year to see how effective triple combination therapy is in these people with severe cystic fibrosis disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triple combination therapy | Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator. |
Timeline
- Start date
- 2019-09-05
- Primary completion
- 2021-02-26
- Completion
- 2021-02-26
- First posted
- 2019-07-31
- Last updated
- 2021-03-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04038710. Inclusion in this directory is not an endorsement.